Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral i...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390/full |
| _version_ | 1818838771782647808 |
|---|---|
| author | Angeliki Datsi Rüdiger V. Sorg |
| author_facet | Angeliki Datsi Rüdiger V. Sorg |
| author_sort | Angeliki Datsi |
| collection | DOAJ |
| description | Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral immune response. Numerous DCV trials have been performed, vaccinating hundreds of GBM patients and confirming feasibility and safety. Many of these studies reported induction of an antitumoral immune response and indicated improved survival after DCV. However, two controlled randomized trials failed to detect a survival benefit. This raises the question of whether the promising concept of DCV may not hold true or whether we are not yet realizing the full potential of this therapeutic approach. Here, we discuss the results of recent vaccination trials, relevant parameters of the vaccines themselves and of their application, and possible synergies between DCV and other therapeutic approaches targeting the immunosuppressive microenvironment of GBM. |
| first_indexed | 2024-12-19T03:43:42Z |
| format | Article |
| id | doaj.art-55e09c7d77b1449082ccac28bdd7cfa3 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-19T03:43:42Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-55e09c7d77b1449082ccac28bdd7cfa32022-12-21T20:37:10ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-11-011210.3389/fimmu.2021.770390770390Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead EndAngeliki DatsiRüdiger V. SorgGlioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral immune response. Numerous DCV trials have been performed, vaccinating hundreds of GBM patients and confirming feasibility and safety. Many of these studies reported induction of an antitumoral immune response and indicated improved survival after DCV. However, two controlled randomized trials failed to detect a survival benefit. This raises the question of whether the promising concept of DCV may not hold true or whether we are not yet realizing the full potential of this therapeutic approach. Here, we discuss the results of recent vaccination trials, relevant parameters of the vaccines themselves and of their application, and possible synergies between DCV and other therapeutic approaches targeting the immunosuppressive microenvironment of GBM.https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390/fulldendritic cellsvaccinationimmunotherapyglioblastomareview (article)glioma |
| spellingShingle | Angeliki Datsi Rüdiger V. Sorg Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End Frontiers in Immunology dendritic cells vaccination immunotherapy glioblastoma review (article) glioma |
| title | Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End |
| title_full | Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End |
| title_fullStr | Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End |
| title_full_unstemmed | Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End |
| title_short | Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End |
| title_sort | dendritic cell vaccination of glioblastoma road to success or dead end |
| topic | dendritic cells vaccination immunotherapy glioblastoma review (article) glioma |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390/full |
| work_keys_str_mv | AT angelikidatsi dendriticcellvaccinationofglioblastomaroadtosuccessordeadend AT rudigervsorg dendriticcellvaccinationofglioblastomaroadtosuccessordeadend |